{
    "symbol": "TCRT",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 12:31:02",
    "content": " For the first quarter of 2022, we reported a net loss of approximately $9.8 million or $0.05 net loss per share, compared to a net loss of approximately $21.6 million or $0.10 net loss per share for the first quarter of 2021. We also plan to invest in a multi-pronged manufacturing strategy to increase capacity, pre-clinically, we are working diligently to advance our membrane bound IL-15 towards an IND filing in the second half of 2023 as well as identify new proprietary TCRs using our hunTR discovery platform."
}